Swiss National Bank raised its stake in Medidata Solutions, Inc. (NASDAQ:MDSO) by 1.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 96,400 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. Swiss National Bank owned approximately 0.17% of Medidata Solutions worth $7,538,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Medidata Solutions by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after buying an additional 208 shares during the last quarter. Parametrica Management Ltd bought a new position in Medidata Solutions in the 2nd quarter valued at approximately $216,000. LS Investment Advisors LLC raised its holdings in Medidata Solutions by 44.6% in the 1st quarter. LS Investment Advisors LLC now owns 3,310 shares of the company’s stock valued at $191,000 after buying an additional 1,021 shares during the last quarter. World Asset Management Inc bought a new position in Medidata Solutions in the 1st quarter valued at approximately $201,000. Finally, Miles Capital Inc. bought a new position in Medidata Solutions in the 1st quarter valued at approximately $202,000. 97.53% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/16/swiss-national-bank-boosts-stake-in-medidata-solutions-inc-mdso.html.

MDSO has been the subject of a number of research reports. BidaskClub lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. SunTrust Banks, Inc. raised their price objective on shares of Medidata Solutions from $80.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, June 27th. J P Morgan Chase & Co raised their price objective on shares of Medidata Solutions to $87.00 and gave the company an “overweight” rating in a report on Tuesday, July 18th. Citigroup Inc. reiterated a “buy” rating and issued a $94.00 price objective (up previously from $77.00) on shares of Medidata Solutions in a report on Monday, July 10th. Finally, Morgan Stanley raised their price objective on shares of Medidata Solutions from $74.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $82.91.

In related news, COO Michael L. Capone sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total value of $372,650.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is currently owned by company insiders.

Medidata Solutions, Inc. (NASDAQ MDSO) opened at 75.86 on Friday. The company has a market cap of $4.30 billion, a price-to-earnings ratio of 122.55 and a beta of 1.81. The firm’s 50-day moving average is $74.69 and its 200 day moving average is $69.86. Medidata Solutions, Inc. has a 12-month low of $46.10 and a 12-month high of $85.92.

Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The firm had revenue of $137.41 million during the quarter, compared to analysts’ expectations of $134.28 million. During the same quarter last year, the firm earned $0.24 earnings per share. The business’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, equities analysts expect that Medidata Solutions, Inc. will post $1.28 earnings per share for the current fiscal year.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.